ADAP Adaptimmune Therapeutics ADRs

Adaptimmune Therapeutics PLC along with its subsidiaries is a clinical-stage biopharmaceutical company. It is engaged in novel cancer immunotherapy products based on its T-cell receptor platform. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$1.11  +0.02 (1.84%)
As of 03/24/2023 15:56:35 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  05/06/2015
Outstanding shares:  154,661,381
Average volume:  561,602
Market cap:   $171,674,133
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BWY4XV3

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%